[Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
OBJECTIVE
To evaluate the efficacy and safety of 0.2% brimonidine administered in patients with glaucoma or ocular hypertension.


METHODS
Twenty-five patients (41 eyes) with primary open-angle glaucoma or ocular hypertension were enrolled in this prospective study. Eye drops of 0.2% brimonidine were used twice daily for 6 months and the patients were examined every month after the treatment, including the trough intraocular pressure (IOP, IOP 12 h after 0.2% brimonidine was administrated) and the peak IOP (IOP 12 h after 0.2% brimonidine was administrated). The visual field was examined every three months.


RESULTS
The use of 0.2% brimonidine significantly lowered the trough IOP and the peak IOP (P < 0.05). Every point of the IOP diurnal curve significantly decreased compared with the baseline (P < 0.05). The visual field had no significant change 3 months or 6 months after the treatment with 0.2% brimonidine. No serious systemic side effect was observed.


CONCLUSIONS
Brimonidine is safe and effective in lowering IOP in glaucoma or ocular hypertension and is well tolerated.
Shi
Jing-ming
JM
Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Jiang
You-qin
YQ
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage*; D000328:Adult; D000068438:Brimonidine Tartrate; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage*
D000316:Adrenergic alpha-Agonists; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate